I hope you enjoyed the first article on Lyme disease. The article described Borrelia burgdorferi phenotypic plasticity, which explains its difficulty to eradicate. The article contained a brief table of signs and symptoms; laboratory biomonitoring; and a brief discussion of the co-infections.
B. burgdorferi (Bb) polymorphism's is an amazing defense mechanism. In an unstressed environment, phenotypically it is an active spirochete with a cell wall. When environmentally stressed, it will change to a cystic form without a cell wall yet is surrounded by a protective biofilm. At a higher environmental stress level, Bb will invade the host's cells and live as intracellular parasite. It can sustain itself in an intracellular state for 3 to 4 months. In this intracellular form, it is completely concealed from the immune system and can return to the active spirochete form in a favorable environment.
Knowing these changes in morphology guides treatment changes that conform to the presentation and eradication of the disease. This second article on Lyme disease (LD) will elucidate LD management. This article will include IV adjunct therapy to current antibiotic and/or herbal treatment of acute LD. Then turn its focus on chronic LD infection, including neuro-Lyme disease and lingering post-treatment symptoms. This article will discuss the use of IV silver nanoparticles for the treatment of LD
Don't forget to follow the references for the science based information.
Pete Muran, M.D.